Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$62.30 +3.5%	$61.19	$39.08 ▼ $86.53	$1.98B	-1.52	50,498 shs	41,002 shs
JANX Janux Therapeutics	$32.55 +1.0%	$29.88	$22.52 ▼ $71.71	$1.92B	3.27	847,610 shs	698,421 shs
SDGR Schrödinger	$25.78 +0.1%	$22.17	$16.60 ▼ $28.47	$1.88B	1.77	839,614 shs	887,608 shs
TBPH Theravance Biopharma	$9.50 -2.6%	$9.10	$7.44 ▼ $10.90	$475.01M	0.14	280,405 shs	223,966 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	+3.52%	+6.71%	-6.60%	+8.54%	+52.21%
JANX Janux Therapeutics	+0.99%	+8.46%	+11.86%	-23.43%	-41.96%
SDGR Schrödinger	+0.12%	-0.81%	+29.16%	+3.29%	+5.48%
TBPH Theravance Biopharma	-2.56%	+2.04%	+2.93%	-1.35%	+5.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLTE Belite Bio	2.9273 of 5 stars	3.5	5.0	2.7	0.8	0.6
JANX Janux Therapeutics	3.0089 of 5 stars	3.5	2.0	2.9	5.0	0.0
SDGR Schrödinger	2.4869 of 5 stars	3.5	1.0	3.4	2.5	0.6
TBPH Theravance Biopharma	1.082 of 5 stars	2.1	0.0	2.7	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLTE Belite Bio	3.00	Buy	$96.67	55.16% Upside
JANX Janux Therapeutics	3.09	Buy	$95.25	192.63% Upside
SDGR Schrödinger	3.00	Buy	$33.00	28.01% Upside
TBPH Theravance Biopharma	2.25	Hold	$11.33	19.30% Upside

Current Analyst Ratings Breakdown

Latest TBPH, BLTE, JANX, and SDGR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/16/2025	SDGR Schrödinger	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $32.00
3/26/2025	BLTE Belite Bio	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
3/18/2025	BLTE Belite Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/18/2025	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $100.00
3/3/2025	JANX Janux Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $70.00
2/28/2025	JANX Janux Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$62.00 ➝ $41.00
2/28/2025	JANX Janux Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$75.00 ➝ $76.00
2/27/2025	SDGR Schrödinger	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $45.00
2/25/2025	TBPH Theravance Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00

(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLTE Belite Bio	N/A	N/A	N/A	N/A	$3.28 per share	N/A
JANX Janux Therapeutics	$10.59M	181.70	N/A	N/A	$7.46 per share	4.36
SDGR Schrödinger	$207.54M	9.07	$0.69 per share	37.42	$7.60 per share	3.39
TBPH Theravance Biopharma	$64.38M	7.38	N/A	N/A	$4.28 per share	2.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLTE Belite Bio	-$31.63M	-$1.18	N/A	N/A	N/A	N/A	-31.94%	-30.73%	5/12/2025 (Estimated)
JANX Janux Therapeutics	-$58.29M	-$1.28	N/A	N/A	N/A	-463.91%	-10.47%	-9.86%	5/6/2025 (Estimated)
SDGR Schrödinger	$40.72M	-$2.57	N/A	N/A	N/A	-91.84%	-35.77%	-24.51%	5/7/2025 (Estimated)
TBPH Theravance Biopharma	-$55.19M	-$1.15	N/A	27.14	N/A	-78.18%	-24.79%	-13.43%	5/8/2025 (Estimated)

Latest TBPH, BLTE, JANX, and SDGR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	BLTE Belite Bio	-$0.37	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	TBPH Theravance Biopharma	-$0.11	N/A	N/A	N/A	$28.08 million	N/A
5/7/2025	Q1 2025	SDGR Schrödinger	-$0.81	N/A	N/A	N/A	$54.60 million	N/A
5/6/2025	Q1 2025	JANX Janux Therapeutics	-$0.42	N/A	N/A	N/A	$0.59 million	N/A
3/17/2025	Q4 2024	BLTE Belite Bio	-$0.30	-$0.32	-$0.02	-$0.32	N/A	N/A
2/27/2025	Q4 2024	JANX Janux Therapeutics	-$0.49	-$0.36	+$0.13	-$0.36	N/A	N/A
2/26/2025	Q4 2024	SDGR Schrödinger	-$0.35	-$0.55	-$0.20	-$0.55	$83.20 million	$88.32 million
2/26/2025	Q4 2024	TBPH Theravance Biopharma	-$0.05	-$0.31	-$0.26	-$0.31	$29.90 million	$18.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
SDGR Schrödinger	N/A	N/A	N/A	N/A	N/A
TBPH Theravance Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLTE Belite Bio	N/A	30.73	30.73
JANX Janux Therapeutics	N/A	38.80	38.80
SDGR Schrödinger	N/A	4.11	4.11
TBPH Theravance Biopharma	N/A	4.97	4.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLTE Belite Bio	0.53%
JANX Janux Therapeutics	75.39%
SDGR Schrödinger	79.05%
TBPH Theravance Biopharma	99.10%

Insider Ownership

Company	Insider Ownership
BLTE Belite Bio	13.29%
JANX Janux Therapeutics	29.40%
SDGR Schrödinger	8.60%
TBPH Theravance Biopharma	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLTE Belite Bio	10	31.84 million	27.61 million	Not Optionable
JANX Janux Therapeutics	30	59.11 million	37.05 million	Optionable
SDGR Schrödinger	790	73.04 million	66.59 million	Optionable
TBPH Theravance Biopharma	359	50.00 million	45.78 million	Optionable

TBPH, BLTE, JANX, and SDGR Headlines

Recent News About These Companies

Zacks Research Issues Positive Outlook for TBPH Earnings

April 29 at 2:55 AM | marketbeat.com

Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress

April 28 at 6:00 AM | prnewswire.com

Q1 EPS Estimate for Theravance Biopharma Lifted by Analyst

April 28 at 2:57 AM | americanbankingnews.com

Rep. George Whitesides Sells Theravance Biopharma, Inc. (NASDAQ:TBPH) Stock

April 28 at 2:02 AM | marketbeat.com

JPMorgan Chase & Co. Reduces Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)

April 27 at 3:08 AM | marketbeat.com

Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

April 24, 2025 | prnewswire.com

Insider Selling: Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Sells 4,000 Shares of Stock

April 24, 2025 | insidertrades.com

Vanguard Group Inc. Lowers Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH)

April 19, 2025 | marketbeat.com

Trexquant Investment LP Buys 50,826 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)

April 12, 2025 | marketbeat.com

Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting

April 7, 2025 | prnewswire.com

Theravance Biopharma to Participate in an Upcoming Investor Conference

March 31, 2025 | prnewswire.com

Why Is Theravance Bio (TBPH) Up 0.4% Since Last Earnings Report?

March 28, 2025 | zacks.com

Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology

March 27, 2025 | prnewswire.com

Theravance Biopharma: Clinical Progress Is Not Enough To Make It Attractive

March 10, 2025 | seekingalpha.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2024 Earnings Call Transcript

February 27, 2025 | msn.com

Theravance's Q4 Loss In Line With Estimates, Sales Beat

February 27, 2025 | zacks.com

Theravance Biopharma reports Q4 EPS (31c), consensus (8c)

February 27, 2025 | markets.businessinsider.com

Theravance Biopharma, Inc. (TBPH) Q4 2024 Earnings Call Transcript

February 26, 2025 | seekingalpha.com

Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates

February 26, 2025 | zacks.com

Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results

February 26, 2025 | prnewswire.com

Earnings To Watch: Theravance Biopharma Inc (TBPH) Reports Q4 2024 Result

February 25, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TBPH, BLTE, JANX, and SDGR Company Descriptions

Belite Bio NASDAQ:BLTE

$62.31 +2.13 (+3.54%)

As of 04/29/2025 04:00 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Janux Therapeutics NASDAQ:JANX

$32.55 +0.32 (+0.99%)

Closing price 04/29/2025 04:00 PM Eastern

Extended Trading

$32.56 +0.02 (+0.05%)

As of 04/29/2025 04:05 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Schrödinger NASDAQ:SDGR

$25.78 +0.03 (+0.12%)

Closing price 04/29/2025 04:00 PM Eastern

Extended Trading

$25.76 -0.02 (-0.08%)

As of 04/29/2025 06:54 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Theravance Biopharma NASDAQ:TBPH

$9.50 -0.25 (-2.56%)

Closing price 04/29/2025 04:00 PM Eastern

Extended Trading

$9.50 0.00 (0.00%)

As of 04/29/2025 05:54 PM Eastern

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time